Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy
Objective - UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the factors associated with the clinical behavior UtS. - Methods - Information on 269 patients with advanced or metastati...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
July 2016
|
| In: |
Gynecologic oncology
Year: 2016, Volume: 142, Issue: 1, Pages: 95-101 |
| ISSN: | 1095-6859 |
| DOI: | 10.1016/j.ygyno.2016.05.016 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ygyno.2016.05.016 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0090825816307405 
|
| Author Notes: | I. Ray-Coquard, E. Rizzo, J.Y. Blay, P. Casali, I. Judson, A. Krarup Hansen, L.H. Lindner, A.P. dei Tos, H. Gelderblom, S. Marreaud, S. Litière, P. Rutkowski, P. Hohenberger, A. Gronchi, W.T. van der Graaf |
| Summary: | Objective - UtS are a group of uncommon tumors representing 1% of malignant neoplasms of the female genital tract, and 7% of sarcomas. The objective of this study was to evaluate the factors associated with the clinical behavior UtS. - Methods - Information on 269 patients with advanced or metastatic first line UtS treated by chemotherapy was available in a database containing information on 3270 patients with advanced soft tissue sarcomas (STS) entered in EORTC-STBSG clinical trials between 1977 and 2010. The chemotherapy was aggregated in 4 categories: anthracyclines alone, ifosfamide alone, the combination of doxorubicin and ifosfamide, and CYVADIC. - Results - Among the 269 UtS pts, there were 231 deaths (median OS 10.4months, 95% CI: 9.1-11.9) and 257 progressions and/or deaths (median PFS 4.1months, 95% CI: 3.5-4.9). Multivariate analyses reported PS (p<0.001) only to be a statistically significant prognostic factor for OS in UtS; for PFS, LMS histology (p=0.025) is associated with a better outcome. There was no relationship between the 4 groups of chemotherapy regimens and impact on clinical outcomes. Histological subtype was significantly correlated with response to chemotherapy (RR: LMS 19% vs other 33%, p=0.026). Ifosfamide single agent yielded only 5% of RR. - Conclusions - Clearly, UtS are very aggressive neoplasms with poor outcome when treated with chemotherapy consisting of anthracyclines with or without ifosfamide or cyclophosphamide. New strategies are urgently needed. |
|---|---|
| Item Description: | Gesehen am 16.03.2020 Available online 24 May 2016 |
| Physical Description: | Online Resource |
| ISSN: | 1095-6859 |
| DOI: | 10.1016/j.ygyno.2016.05.016 |